As a shortage of epinephrine pens continues to grip the U.K., authorities are extending the expiration dates on a second injector.
The FDA, which banned products from a South Korean sterile manufacturer last spring, has now followed up with a warning letter.
EU regulators say they have found the same impurity discovered in valsartan in both losartan and irbesartan.
The punishment, an amount rarely seen in China, includes confiscation of illegal gains and a fine three times those sales.
Here is some news of note for the week.
India’s Dr. Reddy’s Laboratories says it will unload its API manufacturing business to the Middle East-based Neopharma.
Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners but is now officially open.
As the Chinese valsartan maker's shares tumble, the FDA fixed its import alert announcement to show that it applies to only one of its two sites in China.
U.K.-based CDMO Almac is adding to its U.S. operations with a new building at its site in North Carolina where it says it will house 100 new employees.
Israel-based Teva, whose pledge to unload manufacturing plants in its home country sparked strikes, is reportedly close to selling a site there.